A randomized, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GWP42003: GWP42004 plus GWP42003 and GWP42004 alone in the treatment of dyslipedemia in subjects with Type 2 diabetes.

drug protocol number
GWZMD1190
drug sponsor
GW
drug study
Cannabidiol & Tetrahydrocannabivarin
drug trial site
N\A
drug status
Rejected
drug phase